December 2017

Does Erythropoietin monotherapy reduce mortality or moderate/severe disability in neonates with hypoxic ischemic encephalopathy?

HYPOXIC ISCHEMIC ENCEPHALOPATHY HIE is commonly treated with therapeutic hypothermia, but erythropoeitin (EPO) exists both as a monotherapy and an adjunct therapeutic option. This randomized controlled trial studied the use of EPO monotherapy initiated within 6 hours of birth in preventing death or severe disability at 19 months of age in term neonates with moderate or severe HIE. Although further analysis is needed, the trial revealed that EPO monotherapy reduces the risk of death or disability compared to placebo.